Lupanol 3-beta-diglucoside | CAS#120527-58-4

MedKoo Cat#: 528054 | Name: Lupanol 3-beta-diglucoside

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lupanol 3-beta-diglucoside is a bioactive chemcial.

Chemical Structure

Lupanol 3-beta-diglucoside

CAS#120527-58-4

Theoretical Analysis

MedKoo Cat#: 528054

Name: Lupanol 3-beta-diglucoside

CAS#: 120527-58-4

Chemical Formula: C42H72O11

Exact Mass: 752.5075

Molecular Weight: 753.03

Elemental Analysis: C, 66.99; H, 9.64; O, 23.37

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Lupanol 3-beta-diglucoside

IUPAC/Chemical Name

beta-D-Glucopyranoside, (3beta)-lupan-3-yl O-beta-D-glucopyranosyl-

InChi Key

SQLBDGHCDJLXIZ-DXAPHSLFSA-N

InChi Code

InChI=1S/C42H72O11/c1-21(2)22-11-14-38(5)17-18-40(7)23(29(22)38)9-10-28-39(6)15-12-27(37(3,4)26(39)13-16-41(28,40)8)42(35(50)33(48)31(46)25(20-44)52-42)53-36-34(49)32(47)30(45)24(19-43)51-36/h21-36,43-50H,9-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28+,29+,30+,31+,32-,33-,34+,35+,36-,38+,39-,40+,41+,42-/m0/s1

SMILES Code

O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@]1([C@@H]2CC[C@]3(C)[C@@]4([H])CC[C@]5([H])[C@@]6([H])[C@H](C(C)C)CC[C@@](C)6CC[C@](C)5[C@@](C)4CC[C@]([H])3C2(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@@H](CO)O7)O)O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 753.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Odinak MM, Litvinenko IV, Emelin AY, Lobzin VY, Lupanov IA, Kolmakova KA. [Pathomorphological changes in dementia: a priority of domestic researchers]. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(6):28-34. Russian. PubMed PMID: 27723707. 2: Litvinenko IV, Vorob'ev SV, Lobzin VY, Lupanov IA. [Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(9):29-35. Russian. PubMed PMID: 24107877. 3: Odinak MM, Kashin AV, Ememlin AIu, Lupanov IA. [Therapeutic correction of mild cognitive impairment in patients with chronic cerebral ischemia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(5):25-30. Russian. PubMed PMID: 23739499. 4: Lupanov VP. [Value of exercise electrocardiography and other current instrumental studies in the evaluation of percutaneous coronary interventions and in the detection of restenosis]. Ter Arkh. 2010;82(4):67-73. Review. Russian. PubMed PMID: 20481221. 5: Evstifeeva SE, Lupanov VP, Samko AN, Naumov VG. [Assessment of clinical course, prognosis and effectiveness of drug and nondrug treatment of patients with ischemic heart disease and occlusive coronary artery atherosclerosis (data of 5-year prospective follow-up)]. Kardiologiia. 2006;46(6):4-9. Russian. PubMed PMID: 16883216. 6: Aronov DM, Lupanov VP. [Differentiated use of nitrates in ischemic heart disease]. Kardiologiia. 2006;46(1):74-83. Review. Russian. PubMed PMID: 16474313. 7: Kazachkina SS, Balakhonova TV, Lupanov VP, Pogorelova OA, Rogoza AN, Naumov VG. [Effects of isosorbide-5-mononitrate on clinical condition, bicycle ergometry results, endothelium-dependent vasodilation in patients with ischemic heart disease with stable effort angina]. Ter Arkh. 2005;77(10):71-5. Russian. PubMed PMID: 16320691. 8: Orlova EM, Mironova IIu, Matveeva MA, Lupanov VP, Samoĭlenko LE, Naumov VG. [Assessment of antianginal and antiischemic effect of trimetazidine and its effects on myocardial perfusion in patients with ischemic heart disease and stable angina.]. Kardiologiia. 2004;44(9):23-8. Russian. PubMed PMID: 15477771. 9: Lupanov VP, Kazachkina SS, Naumov VG. [Various forms of mononitrates in treating patients with stress angina]. Ter Arkh. 2003;75(1):40-5. Russian. PubMed PMID: 12652955. 10: Titov VN, Lisitsyn DM, Ameliushkina V, Lupanov VP, Polevaia TIu, Kukharchuk VV. [Proportion of alcohols of cholesterol, glycerol and double bonds of fatty acids in blood serum and lipoproteins. Diagnostic significance of hypercholesterolemia]. Klin Lab Diagn. 2002 Dec;(12):3-8. Russian. PubMed PMID: 12587544. 11: Lupanov VP, Chotchaev KhKh, Evstifeeva SE, Deev AD, Naumov VG. [Clinical course of disease and prognosis in patients with ischemic heart disease with stable angina pectoris, caused by stenosing coronary atherosclerosis (data from a a 20-year study]. Ter Arkh. 2002;74(9):13-20. Russian. PubMed PMID: 12418113. 12: Titov VN, Lisitsyn DM, Ameliushkina VA, Lupanov VP, Staroverov II, Osipov SG, Kukharchuk VV. [Double bonds of fatty acids, alcohols glycerol, cholesterol and nonpolar serum lipids. Diagnostic value of hypercholesterolemia]. Klin Lab Diagn. 2002 May;(5):3-8. Russian. PubMed PMID: 12085703. 13: Naumov VG, Lupanov VP, Dotsenko IuV, Tvorogova MG. [Six-month xenical (orlistat) therapy of patients with stable angina pectoris concomitant with obesity and hyperlipidemia]. Ter Arkh. 2002;74(1):47-51. Russian. PubMed PMID: 11878059. 14: Donchenko VG, Buchnov AD, Lupanov AI, Pastukhov IuA. [Methodological and organizational aspects of the psychological support of service in the Navy]. Voen Med Zh. 2001 Jun;322(6):14-22. Russian. PubMed PMID: 11550530. 15: Lupanov VP, Alekseeva IA, Vasil'eva NN, Romasiuk SS, Afanas'eva IuV, Naumov VG. [Comparative study of retard and non-retard forms of isosorbide-5-mononitrate in coronary patients with stable angina pectoris]. Klin Med (Mosk). 2000;78(11):36-8. Russian. PubMed PMID: 11232528. 16: Lupanov VP, Alekseeva IA, Vasil'eva NN, Komar OA, Romasiuk SS, Naumov VG. [Comparison of dinitrate isosorbide retard forms in ischemic heart disease patients with stable effort angina]. Ter Arkh. 2000;72(9):33-6. Russian. PubMed PMID: 11076413. 17: Lupanov VP, Alekseeva IA, Vasil'eva NN, Chotchaev KhKh, Naumov VG. [Comparative study of isosorbide dinitrates and mononitrates in patients with ischemic heart disease and stable angina pectoris caused by stenosing coronary atherosclerosis]. Klin Med (Mosk). 2000;78(9):52-5. Russian. PubMed PMID: 11051743. 18: Anikin VV, Savin VV, Lupanov VP, Razygraev RA. [Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II]. Ter Arkh. 2000;72(8):28-30. Russian. PubMed PMID: 11019422. 19: Tvorogova MG, Lupanov VP, Nuraliev EIu, Zaĭtseva TM, Kukharchuk VV, Titov VN. [A comparison of the hypolipidemic action of probucol at doses of 500 and 1000 mg/day in moderate hyperlipoproteinemia]. Ter Arkh. 1998;70(8):17-21. Russian. PubMed PMID: 9770737. 20: Lupanov VP. [Objective assessment methods of coronary arteries balloon angioplasty]. Ter Arkh. 1998;70(4):74-80. Review. Russian. PubMed PMID: 9612910.